Prostate Cancer

Long-term follow-up of a trial found patients with recurrent prostate cancer lived longer after receiving the pTVG-HP vaccine than GM-CSF alone.

The FDA approved Pluvicto with hormone therapy for PSMA-positive metastatic prostate cancer, helping delay disease progression in patients.

ASCO 2026 highlighted advances in pancreatic, breast, sarcoma, lung and prostate cancers that may reshape treatment.

How a Facebook reunion between two former reporters grew into a vital bond of shared support, hope and courage during their experiences with cancer.

Diabetes drug metformin may mimic exercise effects in prostate cancer, supporting weight, metabolism and overall health during treatment.

A study found microplastics in prostate tumors, with higher levels in cancer tissue, prompting further research into potential links and health effects.

Talzenna plus Xtandi improved progression-free survival in metastatic prostate cancer, delaying disease worsening in a phase 3 trial.

New strategies in mCRPC focus on sequencing, genomics and earlier use of targeted therapies to improve outcomes for patients.

Personalized treatment, exercise and supportive care improve outcomes for patients with metastatic hormone-sensitive prostate cancer.

The CAPTAIN trial shows MRI-guided TULSA preserved erectile and urinary function versus surgery in localized prostate cancer.

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

A stage 4 prostate cancer survivor shares his story of positivity and gratitude.

An analysis found docetaxel plus ADT to be the most cost-effective therapy for HRR+ metastatic hormone-sensitive prostate cancer.

Adding cabazitaxel to hormone therapy and radiation did not improve survival and caused more side effects in high-risk localized prostate cancer.

Adding 177Lu-PSMA-617 to combination therapy improves disease control in PSMA+ mHSPC while maintaining quality of life and pain outcomes.

Adding Xofigo to Xtandi extends survival and delays disease progression in men with metastatic castration-resistant prostate cancer with bone involvement.

CAPItello-281 shows Truqap plus Zytiga extends rPFS in PTEN-deficient mHSPC with manageable toxicity and preserved overall quality of life.

Oncologists highlight key 2026 ASCO GU studies in bladder, prostate, kidney and testicular cancers that could reshape treatment and personalize care.

A PSMA PET scan found more recurrent prostate cancer at low PSA levels than a standard scan, helping guide more potentially curative treatment decisions.

Amid the grief that I have and continue to deal with due to my sister’s death from cancer, I have been blessed with phenomenal support.

The U.S. FDA granted “study may proceed” clearance for a trial of teverelix in patients with advanced prostate cancer and high cardiovascular risk.

A phase 2 trial found oxybutynin safely reduced the frequency and severity of hot flashes in men receiving hormone therapy for prostate cancer.

A real-world study found Erleada reduced the risk of death compared with Nubeqa in patients with metastatic castration-sensitive prostate cancer.

I reflect on cancer and faith, embracing the power of one to pursue health, purpose, and positive change in my life and for others.

Prostate cancer survivors Ronald Wakefield and Ernie Strauss sat down for an interview with CURE.